IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care

被引：0

作者：

Reck, Martin

Srivastava, Minu K.

Wakelee, Heather A.

Felip, Enriqueta

Altorki, Nasser K.

Csoszi, Tibor

Moiseyenko, Vladimir

Akopov, Andrey

Smolin, Alexey

Chella, Antonio

Vallieres, Eric

Martinez-Marti, Alex

Zou, Wei

McNally, V.

Bennett, Elizabeth

Prizant, Hen

Nabet, Barzin

Ballinger, Marcus

Gitlitz, Barbara J.

Zhou, Caicun

机构：

[1] German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany

[2] Genentech Inc, San Francisco, CA USA

[3] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA USA

[4] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[5] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA

[6] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Szolnok, Hungary

[7] GBUZ St Petersburg Clin Res Ctr Specialized Types, St Petersburg, Russia

[8] Pavlov State Med Univ, St Petersburg, Russia

[9] Principal Mil Clin Hosp NA NN Burdenko, Moscow, Russia

[10] Azienda Osped Univ Pisana, Pneumol Unit, Pisa, Italy

[11] Swedish Canc Inst, Seattle, WA USA

[12] Genentech Inc, San Francisco, CA USA

[13] Roche Prod Ltd, Welwyn Garden City, Herts, England

[14] Genentech Inc, S San Fransico, CA USA

[15] Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8522

引用

页数：1

共 25 条

[21] DEFECTIVE MISMATCH REPAIR STATUS AS A PROGNOSTIC BIOMARKER OF DISEASE-FREE SURVIVAL IN STAGE III COLON CANCER PATIENTS TREATED WITH FOLFOX ADJUVANT CHEMOTHERAPY
Zaanan, Aziz
Flejou, Jean-Francxois
Emile, Jean-Francxois
Guetz, Gaetan Des
Cuilliere-Dartigues, Peggy
Malka, David
Lecaille, Cedric
Validire, Pierre
Louvet, Christophe
Rougier, Philippe
De Gramont, Aimery
Bonnetain, Franck
Praz, Francoise
Taieb, Julien
ANNALS OF ONCOLOGY, 2011, 22 : v106 - v106
[22] Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
Zaanan, Aziz
Flejou, Jean-Francois
Emile, Jean-Francois
Des Guetz, Gaetan
Cuilliere-Dartigues, Peggy
Malka, David
Lecaille, Cedric
Validire, Pierre
Louvet, Christophe
Rougier, Philippe
de Gramont, Aimery
Bonnetain, Franck
Praz, Francoise
Taieb, Julien
CLINICAL CANCER RESEARCH, 2011, 17 (23) : 7470 - 7478
[23] A retrospective analysis to evaluate adjuvant chemotherapy after radical surgery on survival and disease recurrence in patients with stage I, II, IIIA non-small cell lung cancer (NSCLC).
Gamaz, M
Ameur, S
Chaouche, H
Bouzid, K
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 706S - 706S
[24] Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients
Westra, JL
Schaapveld, M
Hollema, H
de Boer, JP
Kraak, MMJ
de Jong, D
ter Elst, A
Mulder, NH
Buys, CHCM
Hofstra, RMW
Plukker, JTM
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5635 - 5643
[25] Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR plus NSCLC.
Yue, Dongsheng
Xu, Shi-Dong
Wang, Qun
Li, Xiaofei
Shen, Yi
Zhao, Heng
Chen, Chun
Mao, Weimin
Liu, Wei
Liu, Junfeng
Zhang, Lan-Jun
Ma, Haitao
Li, Qiang
Yang, Yue
Liu, Yongyu
Chen, Haiquan
Zhang, Zhenfa
Zhang, Bin
Gong, Fuyu
Wang, Changli
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 →